Executive interview – VolitionRx: Results from asymptomatic CRC trial reported

Executive interview – VolitionRx: Results from asymptomatic CRC trial reported

VolitionRx recently announced the initial results from a 680-sample study taken from asymptomatic colorectal cancer (CRC) patients. The study demonstrated 80% sensitivity against stage 1 CRC and 66% against high-risk adenomas (at 78% specificity). The company has stated that it is moving on to the 4,300-sample study to determine the final test panel for European launch (results in Q218). This will be followed by a 12,000+ sample blinded study which is expected to complete in H218.


You may also be interested in these:

Investment Companies

Molten Ventures – executive interview

Metals & Mining

Avino Silver & Gold Mines – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free